Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: A case report

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Mise, Koki ^a   Ubara, Yoshifumi ^a   Matsumoto, Masanori ^b   Sumida, Keiichi ^a   Hiramatsu, Rikako ^a   Hasegawa, Eiko ^a   Yamanouchi, Masayuki ^a   Hayami, Noriko ^a   Suwabe, Tatsuya ^a   Hoshino, Junichi ^a   Sawa, Naoki ^a   Ohashi, Kenichi ^a   Kokame, Koichi ^c   Miyata, Toshiyuki ^c   Fujimura, Yoshihiro ^b   Takaichi, Kenmei ^a  

^a TORANOMON HOSPITAL   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type I domain 13); Alternative pathway; C3; Chronic hemodialysis; Complement activation; Congenital thrombotic thrombocytopenic purpura

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; BILIRUBIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOSPORIN; FRESH FROZEN PLASMA; HAPTOGLOBIN; INDIUM; LACTATE DEHYDROGENASE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MIZORIBINE; OKT 3; PREDNISOLONE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTERIOVENOUS MALFORMATION; ARTICLE; ARTIFICIAL EMBOLISM; BRAIN HEMORRHAGE; BRAIN INFARCTION; CASE REPORT; CREATININE BLOOD LEVEL; DRUG PULSE THERAPY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; EXON; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENETIC ANALYSIS; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HETEROZYGOTE; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; JAPANESE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; MISSENSE MUTATION; NEPHRECTOMY; PLASMAPHERESIS; PROTEINURIA; PURPURA; REMISSION; RETROSPECTIVE STUDY; SCINTIGRAPHY; SPLENECTOMY; SUPERIOR MESENTERIC ARTERY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK;

ADULT; FOLLOW-UP STUDIES; HUMANS; MALE; PEDIGREE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RENAL DIALYSIS; TIME FACTORS;

EID: 84880335331     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-156     Document Type: Article

References (21)

1. Von willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B, Blood 2002 100 2 710 713 10.1182/blood-2002-02-0344 12091372 (Pubitemid 34761143)
2. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, et al. Nature 2001 413 6855 488 494 10.1038/35097008 11586351 (Pubitemid 32938741)
3. Structure and function of von willebrand factor. Ruggeri ZM, Thromb Haemost 1999 82 2 576 584 10605754
4. Localization of ADAMTS13 to the stellate cells of human liver. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H, et al. Blood 2005 106 3 922 924 10.1182/blood-2005-01-0152 15855280 (Pubitemid 41076434)
5. ADAMTS13 Is expressed in hepatic stellate cells. Zhou W, Inada M, Lee TP, Benten D, Lyubsky S, Bouhassira EE, Gupta S, Tsai HM, Lab Invest 2005 85 6 780 788 10.1038/labinvest.3700275 15806136 (Pubitemid 40799707)
6. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Manea M, Kristoffersson A, Schneppenheim R, Saleem MA, Mathieson PW, Morgelin M, Bjork P, Holmberg L, Karpman D, Br J Haematol 2007 138 5 651 662 10.1111/j.1365-2141.2007.06694.x 17627784 (Pubitemid 47206716)
7. The kidney in thrombotic thrombocytopenic purpura. Tsai HM, Minerva Med 2007 98 6 731 747 18299685
8. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T, Br J Haematol 2005 129 1 93 100 10.1111/j.1365-2141.2005.05420.x 15801961 (Pubitemid 40524057)
9. von willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, et al. N Engl J Med 1998 339 22 1578 1584 10.1056/NEJM199811263392202 9828245 (Pubitemid 28536132)
10. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y, Transfusion 2006 46 8 1444 1452 10.1111/j.1537-2995.2006. 00914.x 16934083 (Pubitemid 44117975)
11. ADAMTS13 Activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE, Blood 2003 102 1 60 68 10.1182/blood-2003- 01-0193 12637323 (Pubitemid 36759636)
12. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Raife T, Atkinson B, Montgomery R, Vesely S, Friedman K, Transfusion 2004 44 2 146 150 10.1111/j.1537-2995.2004.00626.x 14962303 (Pubitemid 38236374)
13. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE, Blood 2004 103 11 4043 4049 10.1182/blood-2003-11-4035 14982878 (Pubitemid 38685342)
14. Thrombotic thrombocytopenic purpura in childhood. Bouw MC, Dors N, van Ommen H, Ramakers-van Woerden NL, Pediatr Blood Cancer 2009 53 4 537 542 10.1002/pbc.22094 19544391
15. Dissociation between the level of von willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. Snider CE, Moore JC, Warkentin TE, Finch CN, Hayward CP, Kelton JG, Am J Hematol 2004 77 4 387 390 10.1002/ajh.20221 15551280 (Pubitemid 39578324)
16. Ten candidate ADAMTS13 mutations in six french families with congenital thrombotic thrombocytopenic purpura (upshaw-schulman syndrome). Veyradier A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D, Girma JP, J Thromb Haemost 2004 2 3 424 429 10.1111/j.1538-7933.2004.00623.x 15009458 (Pubitemid 40185653)
17. Natural history of upshaw-schulman syndrome based on ADAMTS13 gene analysis in Japan. Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, Murata M, Miyata T, J Thromb Haemost 2011 9 Suppl 1 283 301 21781265
18. Congenital thrombotic thrombocytopenic purpura associated with unilateral moyamoya disease. Park HW, Oh D, Kim N, Cho HY, Moon KC, Chae JH, Ahn HS, Choi Y, Cheong HI, Pediatr Nephrol 2008 23 9 1555 1558 10.1007/s00467-008-0847-5 18481107
19. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Ruiz-Torres MP, Casiraghi F, Galbusera M, Macconi D, Gastoldi S, Todeschini M, Porrati F, Belotti D, Pogliani EM, Noris M, et al. Thromb Haemost 2005 93 3 443 452 15735793 (Pubitemid 40392531)
20. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G, J Am Soc Nephrol 2005 16 5 1177 1183 10.1681/ASN.2005010086 15800115 (Pubitemid 41716501)
21. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Chapin J, Weksler B, Magro C, Laurence J, Br J Haematol 2012 157 6 772 774 10.1111/j.1365-2141.2012.09084.x 22409250